vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $13.7M, roughly 1.9× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -49.7%, a 125.4% gap on every dollar of revenue. BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-2.1M).
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
BCBP vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $13.7M |
| Net Profit | $-12.0M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -86.5% |
| Net Margin | -49.7% | 75.7% |
| Revenue YoY | 13.1% | — |
| Net Profit YoY | -467.6% | 179.1% |
| EPS (diluted) | $-0.73 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $13.7M | ||
| Q3 25 | $26.5M | $19.1M | ||
| Q2 25 | $25.2M | $8.1M | ||
| Q1 25 | $23.8M | $2.9M | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $26.2M | — | ||
| Q2 24 | $20.4M | — | ||
| Q1 24 | $25.3M | — |
| Q4 25 | $-12.0M | $10.4M | ||
| Q3 25 | $4.3M | $-16.3M | ||
| Q2 25 | $3.6M | $-15.8M | ||
| Q1 25 | $-8.3M | $-13.3M | ||
| Q4 24 | $3.3M | — | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -71.9% | -86.5% | ||
| Q3 25 | 21.9% | -10.1% | ||
| Q2 25 | 19.9% | -177.7% | ||
| Q1 25 | -49.2% | -472.7% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 35.7% | — | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 33.0% | — |
| Q4 25 | -49.7% | 75.7% | ||
| Q3 25 | 16.1% | -85.4% | ||
| Q2 25 | 14.2% | -196.0% | ||
| Q1 25 | -35.0% | -452.7% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 25.5% | — | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 23.2% | — |
| Q4 25 | $-0.73 | $-3.74 | ||
| Q3 25 | $0.22 | $-0.11 | ||
| Q2 25 | $0.18 | $-0.16 | ||
| Q1 25 | $-0.51 | $-0.18 | ||
| Q4 24 | $0.17 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $35.3M |
| Total Assets | $3.3B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $304.3M | $35.3M | ||
| Q3 25 | $318.5M | $-8.1M | ||
| Q2 25 | $315.7M | $7.1M | ||
| Q1 25 | $314.7M | $10.7M | ||
| Q4 24 | $323.9M | — | ||
| Q3 24 | $328.1M | — | ||
| Q2 24 | $320.7M | — | ||
| Q1 24 | $320.1M | — |
| Q4 25 | $3.3B | $154.7M | ||
| Q3 25 | $3.4B | $133.7M | ||
| Q2 25 | $3.4B | $133.8M | ||
| Q1 25 | $3.5B | $103.7M | ||
| Q4 24 | $3.6B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.8B | — | ||
| Q1 24 | $3.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $34.9M | $-2.1M |
| FCF MarginFCF / Revenue | 133.3% | -15.3% |
| Capex IntensityCapex / Revenue | 4.0% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-2.0M | ||
| Q3 25 | $8.7M | $-17.5M | ||
| Q2 25 | $10.3M | $-14.5M | ||
| Q1 25 | $5.0M | $29.0M | ||
| Q4 24 | $67.7M | — | ||
| Q3 24 | $43.5M | — | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.3M | — |
| Q4 25 | $34.9M | $-2.1M | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | $-14.9M | ||
| Q1 25 | $4.7M | $29.0M | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $43.4M | — | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.1M | — |
| Q4 25 | 133.3% | -15.3% | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | -184.0% | ||
| Q1 25 | 19.8% | 988.3% | ||
| Q4 24 | 287.5% | — | ||
| Q3 24 | 166.0% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | 0.7% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 0.6% | 5.0% | ||
| Q1 25 | 1.2% | 0.8% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
